Study Confirms Efficacy of Combo Flu, COVID-19 Vaccine for Adults 50+

Recent studies highlight efforts to improve vaccination rates and efficacy for influenza and COVID-19, particularly among adults aged 50 and older. A major Italian hospital study found that vaccination acceptance among healthcare workers peaked during the first COVID-19 year but declined afterward, emphasizing the importance of tailored delivery models and continuous education to sustain vaccine uptake. Moderna's investigational mRNA-1083 vaccine, combining protection against seasonal influenza and SARS-CoV-2, demonstrated noninferior or superior immune responses compared to existing vaccines in a large phase 3 trial, with an acceptable safety profile. Despite promising immunogenicity results, U.S. regulators have requested additional data on the vaccine's real-world effectiveness in reducing disease risk before approval, pushing the expected timeline to 2026. Experts acknowledge the potential benefits of a combined mRNA vaccine in simplifying immunization schedules and improving coverage but note challenges in timing and public acceptance due to differing epidemiology of flu and COVID-19. Overall, these findings support ongoing innovation in vaccine development and delivery strategies to enhance protection against respiratory viruses in vulnerable populations.